emicizumab
roche
['hemlibra']
#interim data from phase iii study presented at #ash22 show #hemlibra (#emicizumab-kxwh) achieved meaningful bleed control in infants from birth $ro 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.